ethyl 5-(2,6-diethylphenylcarbamoyl)-3-[4-(4-methylpiperazin-1-yl)benzoylamino]-5,6-dihydro-4H-pyrrolo[3,4-c]pyrazole-1-carboxylate | 850997-37-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: ethyl 5-(2,6-diethylphenylcarbamoyl)-3-[4-(4-methylpiperazin-1-yl)benzoylamino]-5,6-dihydro-4H-pyrrolo[3,4-c]pyrazole-1-carboxylate
• 英文别名: 5-(2,6-diethylphenylcarbamoyl)-3-[4-(4-methylpiperazin-1-yl)benzoylamino]-5,6-dihydro-4H-pyrrolo[3,4-c]pyrazole-1-carboxylic acid ethyl ester；Ethyl 5-[(2,6-diethylphenyl)carbamoyl]-3-[[4-(4-methylpiperazin-1-yl)benzoyl]amino]-4,6-dihydropyrrolo[3,4-c]pyrazole-1-carboxylate
• CAS: 850997-37-4
• 化学式: C₃₁H₃₉N₇O₄
• 分子量: 573.695
• InChiKey: LSHLJKLHXNTHAN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.9
• 重原子数：
  42
• 可旋转键数：
  8
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.42
• 拓扑面积：
  112
• 氢给体数：
  2
• 氢受体数：
  7

反应信息

• 作为反应物：
  描述：

  ethyl 5-(2,6-diethylphenylcarbamoyl)-3-[4-(4-methylpiperazin-1-yl)benzoylamino]-5,6-dihydro-4H-pyrrolo[3,4-c]pyrazole-1-carboxylate 在 三乙胺 作用下， 以 甲醇 为溶剂， 反应 3.0h， 以83%的产率得到N-(2,6-二乙基苯基)-4,6-二氢-3-[[4-(4-甲基-1-哌嗪基)苯甲酰基]氨基]吡咯并[3,4-c]吡唑-5(1H)-甲酰胺
  参考文献：
  名称：

  Potent and Selective Aurora Inhibitors Identified by the Expansion of a Novel Scaffold for Protein Kinase Inhibition

  摘要：

  Potent and selective Aurora kinase inhibitors were identified from the combinatorial expansion of the 1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazole bi-cycle, a novel and versatile scaffold designed to target the ATP pocket of protein kinases. The most potent compound reported in this study had an IC(50) of 0.027 microM in the enzymatic assay for Aur-A inhibition and IC(50)s between 0.05 microM and 0.5 microM for the inhibition of proliferation of different tumor cell lines.

  DOI：

  10.1021/jm049076m
• 作为产物：
  描述：

  3-氨基-5-叔丁氧羰基-吡咯并[3,4-C]吡唑 在 盐酸 、 N,N-二异丙基乙胺 作用下， 以 四氢呋喃 、 1,4-二氧六环 、 二氯甲烷 为溶剂， 反应 59.0h， 生成 ethyl 5-(2,6-diethylphenylcarbamoyl)-3-[4-(4-methylpiperazin-1-yl)benzoylamino]-5,6-dihydro-4H-pyrrolo[3,4-c]pyrazole-1-carboxylate
  参考文献：
  名称：

  Potent and Selective Aurora Inhibitors Identified by the Expansion of a Novel Scaffold for Protein Kinase Inhibition

  摘要：

  Potent and selective Aurora kinase inhibitors were identified from the combinatorial expansion of the 1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazole bi-cycle, a novel and versatile scaffold designed to target the ATP pocket of protein kinases. The most potent compound reported in this study had an IC(50) of 0.027 microM in the enzymatic assay for Aur-A inhibition and IC(50)s between 0.05 microM and 0.5 microM for the inhibition of proliferation of different tumor cell lines.

  DOI：

  10.1021/jm049076m

文献信息

• [EN] CARBAMOYL DERIVATIVES OF BICYCLIC CARBONYLAMINO-PYRAZOLES AS PRODRUGS<br/>[FR] DÉRIVÉS CARBAMOYLES DE CARBONYLAMINO-PYRAZOLES BICYCLIQUES COMME PROMÉDICAMENTS
  申请人：NERVIANO MEDICAL SCIENCES SRL

  公开号：WO2009138440A1

  公开（公告）日：2009-11-19

  There are provided bicyclic carbonylamino-pyrazoles of formula (I), wherein the variables are as specified in the claims, for use as medicament, in particular for the treatment of diseases due to the malfunctioning of protein kinases (PKs), such as cancer, pharmaceutical compositions comprising such carbamoyl derivatives, and their use as prodrugs of therapeutically active agents. Method of treatment and some new bicyclic carbonylamino-pyrazoles are also object of the present invention.

  提供了公式(I)中的双环羰胺基吡唑化合物，其中变量如索赔中所述，用作药物，特别用于治疗由蛋白激酶（PKs）功能失调引起的疾病，如癌症，包括这种羰胺基衍生物的药物组合物，以及它们作为治疗活性剂的前药的用途。治疗方法和一些新的双环羰胺基吡唑也是本发明的对象。
• CARBAMOYL DERIVATIVES OF BICYCLIC CARBONYLAMINO-PYRAZOLES AS PRODRUGS
  申请人：Pulici Maurizio

  公开号：US20110118278A1

  公开（公告）日：2011-05-19

  There are provided bicyclic carbonylamino-pyrazoles of formula (I), wherein the variables are as specified in the claims, for use as medicament, in particular for the treatment of diseases due to the malfunctioning of protein kinases (PKs), such as cancer, pharmaceutical compositions comprising such carbamoyl derivatives, and their use as prodrugs of therapeutically active agents. Method of treatment and some new bicyclic carbonylamino-pyrazoles are also object of the present invention.

  本发明提供了式(I)的双环羰基氨基吡唑化合物，其中变量如权利要求中所述，用作药物，特别是用于治疗由蛋白激酶（PKs）功能失调引起的疾病，如癌症，包含此类羰酰基衍生物的制药组合物，并将其用作治疗活性剂的前药。本发明还涉及治疗方法和一些新的双环羰基氨基吡唑化合物。
• US8809337B2
  申请人：——

  公开号：US8809337B2

  公开（公告）日：2014-08-19